Performance in a rodent version of the rIGT
| noMD VEH | noMD MIF | MD VEH | MD MIF | Condition × treatment | Condition (noMD vs MD) | Treatment (VEH vs MIF) | |
|---|---|---|---|---|---|---|---|
| #Sugar pellets gained | 548 ± 2.95 | 521 ± 3.77 | 397 ± 2.17 | 544 ± 5.08 | F(1,44) = 3.9; p = 0.054 | F(1,44) = 2.1; p = 0.152 | F(1,44) = 1.9; p = 0.178 |
| #Switches 2nd half | 5.61 ± 0.23 | 6.06 ± 0.24 | 6.25 ± 0.28 | 4.72 ± 0.27 | F(1,44) = 4.5; p = 0.040 | F(1,44) = 0.6; p = 0.459 | F(1,44) = 1.4; p = 0.250 |
| Win-stay (total) | 0.15 ± 0.20 | 0.13 ± 0.19 | 0.05± 0.07 | 0.18 ± 0.24 | F(1,44) = 4.2; p = 0.046 | F(1,44) = 0.4; p = 0.508 | F(1,44) = 1.8; p = 0.192 |
All animals had been subjected to 24-h MD at PND3 or control treatment. Half of the animals were treated with MIF through oral gavage twice daily on PND26–PND28; the other half received VEH. Data represent mean ± SEM; all groups n = 11-12 animals. Visits to the arm are expressed as a fraction of the total number of trials.